Does shining a spotlight on XIAP deficiency bring the role of allogeneic HCT into better focus? - 04/08/22
Doi : 10.1016/j.jaci.2022.06.003
Rebecca A. Marsh, MD ⁎ 
University of Cincinnati and Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
∗Corresponding author: Rebecca A. Marsh, MD, Cincinnati Children’s Hospital, 3333 Burnet Ave, Cincinnati, OH 45229.Cincinnati Children’s Hospital3333 Burnet AveCincinnatiOH45229
Key words : XIAP, XIAP deficiency, X-linked lymphoproliferative disease, X-linked lymphoproliferative disease type 2, XLP, XLP2, X-linked inhibitor of apoptosis, hematopoietic cell transplantation, HCT, inborn error of immunity
Il testo completo di questo articolo è disponibile in PDF.
| Disclosure of potential conflicts of interest: The author declares that she has no relevant conflicts of interest. |
© 2022
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 150 - N° 2
P. 297-298 - Agosto 2022 Ritorno al numero
Articolo precedente
- Blood endotypic signature in atopic dermatitis: The challenge in personalized medicine
- Tom C. Chan, Chia-Yu Chu
- A “LEAP” forward in understanding immune mechanisms of oral tolerance to peanut
- Timothy P. Moran, Michael D. Kulis
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?